H. Stedt

发表

Up-regulation of Mismatch Repair Pathway by Suicide Gene Therapy: Implications on the use of Temozolomide Treatment in Malignant Glioma

S. Ylä-Herttuala, M. Kaikkonen, Nigel R. Parker, 2018 .

Endothelium‐specific overexpression of human vascular endothelial growth factor‐D in mice leads to increased tumor frequency and a reduced lifespan

S. Ylä-Herttuala, E. Pulkkinen, H. Lesch, 2012, The journal of gene medicine.

Soluble vascular endothelial growth factor receptor-1 improves therapeutic efficacy of suicide gene therapy in an angiogenesis-independent manner.

K. Airenne, T. Wirth, S. Ylä-Herttuala, 2014, Human gene therapy.

Improved therapeutic effect on malignant glioma with adenoviral suicide gene therapy combined with temozolomide

K. Airenne, S. Ylä-Herttuala, H. Samaranayake, 2013, Gene Therapy.

Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study

J. Kononen, T. Kuopio, A. Ristimäki, 2022, British Journal of Cancer.

Tomato thymidine kinase-based suicide gene therapy for malignant glioma—an alternative for Herpes Simplex virus-1 thymidine kinase

J. Piškur, S. Ylä-Herttuala, T. Vuorio, 2015, Cancer Gene Therapy.

Gene Therapy of Malignant Glioma Hanna Stedt Gene Therapy of Malignant Glioma Alternative Strategies and Combination Therapies

H. Stedt, H. Stedt, 2015 .

Specific Inhibition of SRC Kinase Impairs Malignant Glioma Growth In Vitro and In Vivo

S. Ylä-Herttuala, I. Kholová, H. Samaranayake, 2012, Molecular therapy. Nucleic acids.

Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study

J. Kononen, H. Sintonen, H. Isoniemi, 2022, Cancers.

Resectability, Resections, Survival Outcomes, and Quality of Life in Older Adult Patients with Metastatic Colorectal Cancer (the RAXO-Study)

J. Kononen, H. Isoniemi, B. Glimelius, 2023, Journal of clinical medicine.

Resectability and resection rates of colorectal liver metastases according to RAS and BRAF mutational status: prospective study

J. Kononen, T. Kuopio, A. Ristimäki, 2022, The British journal of surgery.

Atypical (non‐V600E) BRAF mutations in metastatic colorectal cancer in population and real‐world cohorts

T. Sjöblom, T. Kuopio, H. Sorbye, 2023, International journal of cancer.

Impact of Primary Tumor Location on Demographics, Resectability, Outcomes, and Quality of Life in Finnish Metastatic Colorectal Cancer Patients (Subgroup Analysis of the RAXO Study)

J. Sundström, T. Salminen, R. Ristamäki, 2024, Cancers.